secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2026-07-22T20:28:22+00:00
Accession:  0001213900-26-080414
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mentari raises additional $200M private placement; extends cash runway into 2029
--------------------------------------------------------------------------------

- Additional $200M private placement from Fairmount, ADAR1, Venrock, Blackstone, Janus Henderson, and other healthcare investors.
- Proceeds extend cash runway into 2029 and through Phase 2a readout for PACAP-targeted programs including MT-002.
- Post-merger, pre-Merger Mentari stockholders own ~98.85% of combined company; InMed shareholders ~1.15%; total shares ~601M.
- Private placement expected to close immediately prior to merger completion, concurrent with previously announced $290M placement.
- Combined company to operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/0001213900-26-080414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/ea0298644-8k425_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-080414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer